Form 4: Integra LifeSciences EVP & CHRO Reports Acquisition of Common Stock and Stock Options
SEC Form 4 Filing
Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences, reports acquiring common stock and stock options.
Summary
- On March 11, 2024, Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences Holdings Corp, acquired 3,475 shares of common stock at $0 and 8,283 shares of common stock at $0.
- Following these transactions, Veillon-Berteloot directly owns 25,791 shares of common stock.
- Veillon-Berteloot also acquired 8,027 non-qualified stock options with an exercise price of $36.22, vesting 25% annually over four years starting March 11, 2024, and expiring on March 11, 2032.
- After the transaction, Veillon-Berteloot directly owns 8,027 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard filing indicating insider transactions. The acquisition of shares and options by an executive is generally viewed as a positive sign, but it's not overwhelmingly positive.
Positives
- The acquisition of stock and stock options by a high-ranking executive could be seen as a positive signal about the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.
Stakeholder Impact
- The transactions may influence investor perception of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of transaction: Acquisition of common stock and stock options. |
| 03/11/2024 | Grant date of stock options. |
| 03/11/2032 | Expiration date of stock options. |
| 03/13/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.